p-Cresyl sulfate
(Synonyms: 对甲酚硫酸铵盐,p-Tolyl sulfate) 目录号 : GC17516
对甲酚是一种与蛋白质结合的尿毒症滞留溶质1。
Cas No.:3233-58-7
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
| Cell experiment [1]: | |
|
Cell lines |
Human umbilical vein endothelial cells |
|
Preparation method |
Limited solubility. General tips for obtaining a higher concentration: Please warm the tube at 37 ℃ for 10 minutes and/or shake it in the ultrasonic bath for a while. Stock solution can be stored below -20℃ for several months. |
|
Reaction Conditions |
24 h |
|
Applications |
Without and with HSA, 10 mug/mL, 25 mug/mL and 50 mug/mL p-cresol induce a decrease in endothelial cell proliferation by 21%, 38% and 54%, respectively. Without HSA, endothelial wound repair in monolayers treated with p-cresol is prominently lower than in cells treated with control medium. 10 mug/mL, 25 mug/mL and 50 mug/mL p-cresol reduce endothelial wound repair by 19%, 28% and 40%, respectively. With HSA, only 50 mug/mL p-cresol prominently blocks endothelial wound repair. |
| Animal experiment [2]: | |
|
Animal models |
Rat |
|
Dosage form |
Intravenously injection of p-cresol (10 mg/kg) in rats with normal and decreased renal function |
|
Preparation method |
Dissolved in isotonic saline |
|
Applications |
P-cresol was injected in mice with normal and decreased renal function, and compared the results with those obtained for creatinine (60 mg/kg) under similar conditions. In rats with decreased renal function, p-cresol serum concentration displays a minimal decline, in contrast to rats with normal renal function. In rats with normal renal function, 21.0±10.0% of the injected p-cresol was excreted in urine. In rats with renal failure, the amount is 6.7±7.5%. |
|
Other notes |
Please test the solubility of all compounds indoor, and the actual solubility may slightly differ with the theoretical value. This is caused by an experimental system error and it is normal. |
|
References: 1. Dou L, Bertrand E, Cerini C, et al. The uremic solutes p-cresol and indoxyl sulfate inhibit endothelial proliferation and wound repair. Kidney international, 2004, 65(2): 442-451. 2. Lesaffer G, De Smet R, D'Heuvaert T et al. Comparative kinetics of the uremic toxin p-cresol versus creatinine in rats with and without renal failure. Kidney Int. 2003 Oct; 64(4):1365-73. |
|
The p-Cresol is a protein-bound uremic retention solute 1.
Free p-Cresol was found to be a cardiovascular risk factor in non-diabetic hemodialysis patients. In patients with diabetes, the level of both free p-cresol and total p-cresol were markedly higher. In patients treated by hemodialysis, the levels of these two forms of p-cresol were also significantly higher than that of patients treated by hemodiafiltration. The univariate cox proportional hazard analysis showed that the concentration of free p-cresol was obviously associated with cardiovascular disease (CVD). Quite many patients with high free p-cresol concentrations had new fatal or non-fatal cardiovascular events. Besides that, p-cresol was also found to inhibit cell proliferation. It inhibited the proliferation of cultured endothelial cells by 26% without affecting cell viability. Moreover, p-cresol treatment reduced endothelial wound repair by 19%, 28% and 40% at concentrations of 10, 25 and 50 μg/ml, respectively 1,2.
References:
1.?Meijers B K I, Bammens B, De Moor B, et al. Free p-cresol is associated with cardiovascular disease in hemodialysis patients. Kidney international, 2008, 73(10): 1174-1180.
2.?Dou L, Bertrand E, Cerini C, et al. The uremic solutes p-cresol and indoxyl sulfate inhibit endothelial proliferation and wound repair. Kidney international, 2004, 65(2): 442-451.
对甲酚是一种与蛋白质结合的尿毒症滞留溶质1。
游离对甲酚被发现是非糖尿病血液透析患者的心血管危险因素。在糖尿病患者中，游离对甲酚和总对甲酚的水平明显更高。在接受血液透析治疗的患者中，这两种形式的对甲酚水平也明显高于接受血液透析滤过治疗的患者。单变量cox比例风险分析显示游离对甲酚浓度与心血管疾病（CVD）明显相关。许多游离对甲酚浓度高的患者发生了新的致命或非致命心血管事件。除此之外，还发现对甲酚可抑制细胞增殖。它抑制培养的内皮细胞增殖 26%，而不影响细胞活力。此外，浓度为 10、25 和 50 μg/ml 的对甲酚治疗分别使内皮伤口修复减少了 19%、28% 和 40% 1,2。
| Cas No. | 3233-58-7 | SDF | |
| 别名 | 对甲酚硫酸铵盐,p-Tolyl sulfate | ||
| 化学名 | p-tolyl hydrogen sulfate | ||
| Canonical SMILES | CC1=CC=C(OS(O)(=O)=O)C=C1 | ||
| 分子式 | C7H8O4S | 分子量 | 188.20 |
| 溶解度 | ≥ 30.1mg/mL in DMSO, ≥ 50mg/mL in Water | 储存条件 | Store at -20°C |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 5.3135 mL | 26.5675 mL | 53.135 mL |
| 5 mM | 1.0627 mL | 5.3135 mL | 10.627 mL |
| 10 mM | 0.5313 mL | 2.6567 mL | 5.3135 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。